BREAKING: Tech Futures Jump On Megacap Earnings Biogen stock popped Wednesday after the biotech giant asked the Food and Drug Administration to approve its controversial Alzheimer's treatment, aducanumab."The aducanumab (application) is the first filing for FDA approval of a treatment that addresses the clinical decline associated with this devastating condition, as well as the pathology of the disease," Chief Executive Michel Vounatsos said in a written statement.